Oxygen-generating microparticles downregulate HIF-1α expression, increase cardiac contractility, and mitigate ischemic injury
Acta Biomaterialia · 2023-03 · 159 · 211-225
DOI: 10.1016/j.actbio.2023.01.030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2023-03. Verfasst von Kalpana Mandal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, USA. Electronic address: kmandal@terasaki.org. Hauptthemen laut MEDLINE: Myocardial Ischemia, Oxygen. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIGMS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Myocardial hypoxia is the low oxygen tension in the heart tissue implicated in many diseases, including ischemia, cardiac dysfunction, or after heart procurement for transplantation. Oxygen-generating microparticles have recently emerged as a potential strategy for supplying oxygen to sustain cell survival, growth, and tissue functionality in hypoxia. Here, we prepared oxygen-generating microparticles with poly D,L-lactic-co-glycolic acid, and calcium peroxide (CPO), which yielded a continuous morphology capable of sustained oxygen release for up to 24 h. We demonstrated that CPO microparticles increased primary rat cardiomyocyte metabolic activity while not affecting cell viability during hypoxia. Moreover, hypoxia-inducible factor (HIF)-1α, which is upregulated during hypoxia, can be downregulated by delivering oxygen using CPO microparticles. Single-cell traction force microscopy data demonstrated that the reduced energy generated by hypoxic cells could be restored using CPO microparticles. We engineered cardiac tissues that showed higher contractility in the presence of CPO microparticles compared to hypoxic cells. Finally, we observed reduced myocardial injuries in ex vivo rabbit hearts treated with CPO microparticles. In contrast, an acute early myocardial injury was observed for the hearts treated with control saline solution in hypoxia. In conclusion, CPO microparticles improved cell and tissue contractility and gene expression while reducing hypoxia-induced myocardial injuries in the heart. STATEMENT OF SIGNIFICANCE: Oxygen-releasing microparticles can reduce myocardial ischemia, allograft rejection, or irregular heartbeats after heart transplantation. Here we present biodegradable oxygen-releasing microparticles that are capable of sustained oxygen release for more than 24 hrs. We then studied the impact of sustained oxygen release from microparticles on gene expresseion and cardiac cell and tissue function. Previous studies have not measured cardiac tissue or cell mechanics during hypoxia, which is important for understanding proper cardiac function and beating. Using traction force microscopy and an engineered tissue-on-a-chip, we demonstrated that our oxygen-releasing microparticles improve cell and tissue contractility during hypoxia while downregulating the HIF-1α expression level. Finally, using the microparticles, we showed reduced myocardial injuries in rabbit heart tissue, confirming the potential of the particles to be used for organ transplantation or tissue engineering.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, USA. Electronic address: kmandal@terasaki.org.
- Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, USA; California NanoSystems Institute, University of California, Los Angeles, California 90095, USA.
- Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, USA; California NanoSystems Institute, University of California, Los Angeles, California 90095, USA; Department of Bioengineering, University…
- Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, USA.
- Department of Bioengineering, University of California, Los Angeles, California 90095, USA.
- Terasaki Institute for Biomedical Innovation, Los Angeles, California 90064, USA. Electronic address: mdokmeci@terasaki.org.
Förderung
- NIAMS NIH HHS
- NIGMS NIH HHS
- NCI NIH HHS
- American Heart Association Inc
- National Institutes of Health
Zitieren
APA
Mandal, K., Sangabathuni, S., Haghniaz, R., Kawakita, S., Mecwan, M., Nakayama, A., Zhang, X., Edalati, M., Huang, W., Lopez Hernandez, A., Jucaud, V., Dokmeci, M. R., & Khademhosseini, A. (2023). Oxygen-generating microparticles downregulate HIF-1α expression, increase cardiac contractility, and mitigate ischemic injury. Acta Biomaterialia, 159, 211-225. https://doi.org/10.1016/j.actbio.2023.01.030
Vancouver
Mandal K, Sangabathuni S, Haghniaz R, Kawakita S, Mecwan M, Nakayama A, et al. Oxygen-generating microparticles downregulate HIF-1α expression, increase cardiac contractility, and mitigate ischemic injury. Acta Biomaterialia. 2023;159:211-225. doi:10.1016/j.actbio.2023.01.030
BibTeX
@article{Mandal2023,
author = {Mandal, Kalpana and Sangabathuni, Sivakoti and Haghniaz, Reihaneh and Kawakita, Satoru and Mecwan, Marvin and Nakayama, Aya and Zhang, Xuexiang and Edalati, Masoud and Huang, Wei and Lopez Hernandez, Ana and Jucaud, Vadim and Dokmeci, Mehmet R and Khademhosseini, Ali},
title = {Oxygen-generating microparticles downregulate HIF-1α expression, increase cardiac contractility, and mitigate ischemic injury},
journal = {Acta Biomaterialia},
year = {2023},
volume = {159},
pages = {211--225},
doi = {10.1016/j.actbio.2023.01.030}
}
EUVIMED